Latest & greatest articles for heart failure

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heart failure or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heart failure and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heart failure

121. Stem cells for heart failure: What is the evidence?

Stem cells for heart failure: What is the evidence? Stem cells for heart failure: What is the evidence? | Clinical Correlations Stem cells for heart failure: What is the evidence? September 27, 2017 By Maxine Wallis Stachel, MD Peer Reviewed The Scale of the Problem Despite decades of rigorous data collection, drug research, patient education and evidence-based practice, ischemic heart disease (IHD) and congestive heart failure (CHF) remain among the most deadly diagnoses in America (...) . The standardization of medical therapy and surgical revascularization have reduced morbidity and mortality, but these measures have not kept pace with the burden and cost of disease, which continue to expand as the population ages and more patients survive acute myocardial infarction. IHD and CHF are heterogeneous and multifactorial, but their common course is marked by dysfunctional cell signaling and the death of cardiomyocytes, leading to hibernating or scarred cardiac tissue and decreased pump function

Clinical Correlations2017

122. Effect of early follow-up after hospital discharge on outcomes in patients with heart failure or chronic obstructive pulmonary disease: a systematic review

Effect of early follow-up after hospital discharge on outcomes in patients with heart failure or chronic obstructive pulmonary disease: a systematic review Effect of early follow-up after hospital discharge on outcomes in patients with heart failure or chronic obstructive pulmonary disease: a systematic review Effect of early follow-up after hospital discharge on outcomes in patients with heart failure or chronic obstructive pulmonary disease: a systematic review Health Quality Ontario Record (...) Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Health Quality Ontario. Effect of early follow-up after hospital discharge on outcomes in patients with heart failure or chronic obstructive pulmonary disease: a systematic review. Toronto: Health Quality Ontario (HQO). Ontario health technology assessment series; 17(8). 2017 Authors' conclusions Based

Health Technology Assessment (HTA) Database.2017

123. Takayasu arteritis presented with acute heart failure: case report and review of literature

Takayasu arteritis presented with acute heart failure: case report and review of literature 28960930 2018 07 16 2018 11 13 2055-5822 4 4 2017 11 ESC heart failure ESC Heart Fail Takayasu arteritis presented with acute heart failure: case report and review of literature. 649-654 10.1002/ehf2.12174 Acute heart failure due to myocarditis is not common in Takayasu arteritis, let alone in combination with thrombosis affecting both ventricles and pulmonary arteries. The concomitant infection of non (...) -tuberculosis mycobacterium further complicates the clinical scenario and poses challenges for implementation of tailored treatments. This case report describes a teenage girl with a history of intermittent claudication and Erythema Nodosum who developed acute heart failure. Detailed clinical investigations and imaging techniques confirmed the diagnosis. © 2017 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology. An Xuanqi X Department

ESC heart failure2017 Full Text: Link to full Text with Trip Pro

124. Vascular phenotypes of acute decompensated vs. new‐onset heart failure: treatment implications

Vascular phenotypes of acute decompensated vs. new‐onset heart failure: treatment implications 28960929 2018 07 16 2018 11 13 2055-5822 4 4 2017 11 ESC heart failure ESC Heart Fail Vascular phenotypes of acute decompensated vs. new-onset heart failure: treatment implications. 679-685 10.1002/ehf2.12210 Acute heart failure (HF) is a frequent and life-threatening syndrome with heterogeneous clinical, haemodynamic, and neurohormonal features. This article describes the vascular phenotypes (...) associated with acute decompensated chronic HF (ADCHF), and new-onset acute HF (NOAHF). Worsening of chronic HF occurs with full activation of adaptive mechanisms that maintain blood pressure (BP) and systemic perfusion. Rapid onset of HF in the setting of previous normal functioning heart not only does not allow full activation of adaptive mechanisms but also generates inappropriate responses from systemic endothelium leading to low BP/hypotension. Consequently, the treatment of ADCHF is based

ESC heart failure2017 Full Text: Link to full Text with Trip Pro

125. Focused echocardiography and lung ultrasound protocol for guiding treatment in acute heart failure

Focused echocardiography and lung ultrasound protocol for guiding treatment in acute heart failure 28960894 2018 10 25 2018 11 13 2055-5822 5 1 2018 02 ESC heart failure ESC Heart Fail Focused echocardiography and lung ultrasound protocol for guiding treatment in acute heart failure. 120-128 10.1002/ehf2.12208 There is little evidence-based therapy existing for acute heart failure (AHF), hospitalizations are lengthy and expensive, and optimal monitoring of AHF patients during in-hospital (...) ). No significant difference in adverse events occurred between the groups. The CaTUS-guided therapy for AHF resulted in greater decongestion during shorter hospitalization without increased adverse events in this small pilot study and might be associated with a better post-discharge prognosis. © 2017 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology. Öhman Jonas J Division of Internal Medicine and Cardiology, Turku University Hospital, Turku

ESC heart failure2017 Full Text: Link to full Text with Trip Pro

126. Autonomic dysfunction is associated with cardiac remodelling in heart failure patients

Autonomic dysfunction is associated with cardiac remodelling in heart failure patients 28960944 2018 10 25 2018 11 13 2055-5822 5 1 2018 02 ESC heart failure ESC Heart Fail Autonomic dysfunction is associated with cardiac remodelling in heart failure patients. 46-52 10.1002/ehf2.12223 Orthostatic hypotension (OH) is a cardinal sign of autonomic dysfunction and a common co-morbidity in heart failure (HF). The role of autonomic dysfunction in the development of structural cardiac anomalies in HF (...) patients has not been sufficiently explored. We aimed to assess relations between orthostatic blood pressure (BP) responses during active standing and echocardiographic changes in a series of patients admitted for HF. One hundred and forty-nine patients hospitalized for HF [mean age: 74 years; 30% women; ejection fraction (LVEF) 40 ± 16%] were examined with conventional echocardiograms and active-standing test. Associations of cardiac remodelling parameters with the difference between supine

ESC heart failure2017 Full Text: Link to full Text with Trip Pro

127. Anorexia, functional capacity, and clinical outcome in patients with chronic heart failure: results from the Studies Investigating Co‐morbidities Aggravating Heart Failure (SICA‐HF)

Anorexia, functional capacity, and clinical outcome in patients with chronic heart failure: results from the Studies Investigating Co‐morbidities Aggravating Heart Failure (SICA‐HF) 28960880 2018 07 16 2018 11 13 2055-5822 4 4 2017 11 ESC heart failure ESC Heart Fail Anorexia, functional capacity, and clinical outcome in patients with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). 448-457 10.1002/ehf2.12209 We aimed (...) to assess determinants of anorexia, that is loss of appetite in patients with heart failure (HF) and aimed to further elucidate the association between anorexia, functional capacity, and outcomes in affected patients. We assessed anorexia status among 166 patients with HF (25 female, 66 ± 12 years) who participated in the Studies Investigating Co-morbidities Aggravating HF. Anorexia was assessed by a 6-point Likert scale (ranging from 0 to 5), wherein values ≥1 indicate anorexia. Functional capacity

ESC heart failure2017 Full Text: Link to full Text with Trip Pro

128. Depressed patients with heart failure may not improve with escitalopram

Depressed patients with heart failure may not improve with escitalopram Depressed patients with heart failure may not improve with escitalopram Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Depressed patients with heart failure may not improve with escitalopram View/ Open Date 2017-07 Format Metadata Abstract Bottom (...) line: Escitalopram does not decrease mortality, rehospitalization rates, or depression symptoms among depressed patients with heart failure. This conclusion may not apply to all depressed patients and the study population was not large enough to definitively rule out a benefit in depression symptoms. URI Part of Citation Evidence-based practice 20, no. 7 (2017): E13 Collections hosted by hosted by

Evidence Based Practice 2017

129. The prognostic value of brain natriuretic peptide in patients with heart failure and left ventricular ejection fraction higher than 60%: a sub‐analysis of the J‐MELODIC study

The prognostic value of brain natriuretic peptide in patients with heart failure and left ventricular ejection fraction higher than 60%: a sub‐analysis of the J‐MELODIC study 28941144 2018 10 25 2018 11 13 2055-5822 5 1 2018 02 ESC heart failure ESC Heart Fail The prognostic value of brain natriuretic peptide in patients with heart failure and left ventricular ejection fraction higher than 60%: a sub-analysis of the J-MELODIC study. 36-45 10.1002/ehf2.12206 Cardiac function varies (...) in the population of patients with heart failure (HF) with preserved left ventricular ejection fraction (LVEF; HFpEF). This study investigated the heterogeneity of clinical features associated with HF and the prognostic value of BNP levels in patients with HFpEF. The study enrolled 288 patients with stable HF and serum creatinine <1.5 mg/dL who were part of the original J-MELODIC study cohort. They were categorized as having HF with reduced LVEF (HFrEF; EF ≤ 40%, n = 83) or as having HFpEF (EF > 40%, n = 205

ESC heart failure2017 Full Text: Link to full Text with Trip Pro

130. Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction: Association With Baseline Disease Severity and Subsequent Outcome

Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction: Association With Baseline Disease Severity and Subsequent Outcome 28768311 2018 11 13 2380-6591 2 9 2017 Sep 01 JAMA cardiology JAMA Cardiol Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction: Association With Baseline Disease Severity and Subsequent Outcome. 995-1006 10.1001/jamacardio.2017.2511 Among myriad changes occurring during the evolution (...) of heart failure with preserved ejection fraction (HFpEF), cardiomyocyte-extracellular matrix interactions from excess collagen may affect microvascular, mechanical, and electrical function. To investigate whether myocardial fibrosis (MF) is similarly prevalent both in those with HFpEF and those at risk for HFpEF, similarly associating with disease severity and outcomes. Observational cohort study from June 1, 2010, to September 17, 2015, with follow-up until December 14, 2015, at a cardiovascular

JAMA cardiology2017 Full Text: Link to full Text with Trip Pro

131. Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial

Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial 28700781 2018 11 13 2380-6591 2 9 2017 Sep 01 JAMA cardiology JAMA Cardiol Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial. 950-958 10.1001/jamacardio.2017.2198 Persistent congestion is associated with worse outcomes in acute heart failure (AHF). Mineralocorticoid receptor antagonists administered at high doses may relieve congestion (...) difference in the log NT-proBNP reduction between the 2 groups (-0.55 [95% CI, -0.92 to -0.18] with high-dose spironolactone and -0.49 [95% CI, -0.98 to -0.14] with usual care, P = .57). None of the secondary end point or day-30 all-cause mortality or heart failure hospitalization rate differed between the 2 groups. The changes in serum potassium and estimated glomerular filtration rate at 24, 48, 72, and 96 hours. were similar between the 2 groups. Adding treatment with high-dose spironolactone to usual

JAMA cardiology2017 Full Text: Link to full Text with Trip Pro

132. Targeting the Correct Population When Designing Transitional Care Programs for Medicare Patients Hospitalized With Heart Failure

Targeting the Correct Population When Designing Transitional Care Programs for Medicare Patients Hospitalized With Heart Failure 28975198 2018 11 13 2380-6591 2 11 2017 Nov 01 JAMA cardiology JAMA Cardiol Targeting the Correct Population When Designing Transitional Care Programs for Medicare Patients Hospitalized With Heart Failure. 1274-1275 10.1001/jamacardio.2017.3089 Ahmad Faraz S FS Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago

JAMA cardiology2017 Full Text: Link to full Text with Trip Pro

133. Clinical practices and attitudes regarding the diagnosis and management of heart failure: findings from the CORE Needs Assessment Survey

Clinical practices and attitudes regarding the diagnosis and management of heart failure: findings from the CORE Needs Assessment Survey 28921886 2018 10 25 2018 11 13 2055-5822 5 1 2018 02 ESC heart failure ESC Heart Fail Clinical practices and attitudes regarding the diagnosis and management of heart failure: findings from the CORE Needs Assessment Survey. 172-183 10.1002/ehf2.12205 CORE is a continuing medical education initiative designed to support the evidence-based management of heart failure (...) (HF) in the primary and secondary care settings. The goal of the CORE Needs Assessment Survey is to describe current clinical practice patterns and attitudes among global stakeholders in HF care. The CORE Steering Committee guided the development of survey questions to assess clinical practice, confidence, and attitudes/perceptions among cardiologists, primary care physicians, and nurses involved in HF management. In total, 346 healthcare professionals from Australia (n = 59), Austria (n = 59

ESC heart failure2017 Full Text: Link to full Text with Trip Pro

134. Ivabradine in Children With Dilated Cardiomyopathy and Symptomatic Chronic Heart Failure

Ivabradine in Children With Dilated Cardiomyopathy and Symptomatic Chronic Heart Failure 28859790 2017 09 01 2017 09 13 2017 09 13 1558-3597 70 10 2017 Sep 05 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Ivabradine in Children With Dilated Cardiomyopathy and Symptomatic Chronic Heart Failure. 1262-1272 S0735-1097(17)38815-0 10.1016/j.jacc.2017.07.725 Heart rate reduction as a therapeutic target has been investigated in adults with heart failure (HF). Ivabradine has shown (...) promising efficacy, but has not been evaluated in children. Currently, treatment recommendations for chronic pediatric HF are based mainly on chronic HF guidelines for adults. The authors explored the dose-response relationship of ivabradine in children with dilated cardiomyopathy and symptomatic chronic HF. The primary endpoint was ≥20% reduction in heart rate from baseline without inducing bradycardia or symptoms. This was a randomized, double-blind, placebo-controlled, phase II/III study with 12

EvidenceUpdates2017

135. Impact of an Age-Adjusted Co-morbidity Index on Survival of Patients With Heart Failure Implanted With Cardiac Resynchronization Therapy Devices

Impact of an Age-Adjusted Co-morbidity Index on Survival of Patients With Heart Failure Implanted With Cardiac Resynchronization Therapy Devices 28784235 2017 08 08 2017 09 14 2017 09 14 1879-1913 120 7 2017 Oct 01 The American journal of cardiology Am. J. Cardiol. Impact of an Age-Adjusted Co-morbidity Index on Survival of Patients With Heart Failure Implanted With Cardiac Resynchronization Therapy Devices. 1158-1165 S0002-9149(17)31118-9 10.1016/j.amjcard.2017.06.056 Age is an adverse (...) prognostic factor in patients with heart failure. We aimed to assess the impact of age and noncardiac co-morbidities in the outcome of patients undergoing cardiac resynchronization therapy (CRT), and determine which of these two factors is the most important predictor of survival. The study involved a single-center retrospective assessment of 697 consecutive CRT implants during a 12-year period. Patient co-morbidity profile was assessed using the Charlson Co-morbidity Index (CCI) and the Charlson Age-Co

EvidenceUpdates2017

136. An evaluation of involving family caregivers in the self-care of heart failure patients on hospital readmission: Randomised controlled trial (the FAMILY study)

An evaluation of involving family caregivers in the self-care of heart failure patients on hospital readmission: Randomised controlled trial (the FAMILY study) 28772186 2017 08 03 2017 09 22 1873-491X 75 2017 Jul 25 International journal of nursing studies Int J Nurs Stud An evaluation of involving family caregivers in the self-care of heart failure patients on hospital readmission: Randomised controlled trial (the FAMILY study). 101-111 S0020-7489(17)30167-0 10.1016/j.ijnurstu.2017.07.015 (...) The prevalence of heart failure is increasing in Lebanon but to date there is no systematic evaluation of a disease management intervention. The aim of this study was to evaluate the effect of involving family caregivers in the self-care of patients with heart failure on the risk of hospital readmission. A multi-site, block randomised controlled trial. The study was conducted over a 13-month period in three tertiary medical centres in Beirut and Mount Lebanon, Lebanon. Adult patients presenting

EvidenceUpdates2017

137. Quality of Care and Outcomes of Heart Failure Among Patients With Schizophrenia in Denmark

Quality of Care and Outcomes of Heart Failure Among Patients With Schizophrenia in Denmark 28774428 2017 08 04 2017 09 01 2017 09 01 1879-1913 120 6 2017 Sep 15 The American journal of cardiology Am. J. Cardiol. Quality of Care and Outcomes of Heart Failure Among Patients With Schizophrenia in Denmark. 980-985 S0002-9149(17)31035-4 10.1016/j.amjcard.2017.06.027 Research on the association between schizophrenia and the quality of care and clinical outcomes of heart failure (HF) remains sparse (...) . This nationwide study compared the quality of care and clinical outcomes of HF among Danish patients with and without schizophrenia. In a population-based cohort study, we identified 36,718 patients with incident HF with hospital contacts, including 108 with schizophrenia, using Danish registries between 2004 and 2013. High quality of HF care was defined as receiving ≥ 80% guideline-recommended process-performance measures of care. Potential predictors of HF care among patients with schizophrenia included

EvidenceUpdates2017

138. Entresto (sacubitril, valsartan) - treatment of heart failure

Entresto (sacubitril, valsartan) - treatment of heart failure Entresto (sacubitril, valsartan) × Insert searchphrase to search the website Insert searchphrase to search the website > > > Entresto (sacubitril, valsartan) Conclusion Entresto is the first medicine in the class of combined angiotensin receptor neprilysin inhibitors (ARNI) containing valsartan and sacubitril. It is indicated for the treatment of heart failure as an alternative to angiotensin converting enzyme (ACE (...) ) inhibitors/angiotensin II receptor blockers (ARB). The active ingredient has proven to have a convincing effect on both survival and readmission rates in patients with heart failure who remain symptomatic despite treatment with ACE inhibitors/ARBs at the maximum dose. Treatment should primarily be started by cardiologists experienced in the treatment of patients with heart failure. It is expected that the monitoring of patients up-titrated to the maintenance dose of Entresto are transferred to their GPs. The profile

Danish Pharmacotherapy Reviews2017

139. Should Beta Blockers be Used in Heart Failure with Preserved Ejection Fraction?

Should Beta Blockers be Used in Heart Failure with Preserved Ejection Fraction? Should Beta Blockers be Used in Heart Failure with Preserved Ejection Fraction? | Clinical Correlations Should Beta Blockers be Used in Heart Failure with Preserved Ejection Fraction? August 23, 2017 By Lauren Christene Strazzulla Peer Reviewed The lifetime risk for developing heart failure from age 55 on is 33% for men and 28.5% for women, and as the population ages, there is an increasing [1, 2]. Heart failure is (...) divisible into 2 distinct entities: those with left ventricular systolic dysfunction and those with cardiovascular compromise that does not decrease LV ejection fraction, which is [3]. While these 2 subgroups may present similarly, they develop through different pathophysiological mechanisms. In heart failure with reduced ejection fraction (HFrEF), systolic function is impaired [4]. On the other hand, HFpEF is a heterogeneous and poorly understood condition, and its exact causes remain unclear

Clinical Correlations2017